Balance Sheet ImprovementRecovery to positive equity and zero reported debt in FY2025 materially improves solvency and financial flexibility. Over a multi-month horizon this reduces refinancing risk, supports discretionary investment or M&A, and gives management room to execute a turnaround despite prior volatility.

Life-sciences SpecializationA focused life-sciences software and services model creates durable competitive advantage via regulatory domain expertise, long sales cycles, and sticky client relationships. This specialization supports recurring contracts and cross-sell between software and consulting, aiding revenue stability when demand returns.

Historic Cash GenerationPrior periods of strong operating and free cash flow show the business can be cash-generative under healthier revenue conditions. This indicates structural ability to self-fund operations and investment if revenue recovery occurs, reducing long-term reliance on external capital compared with never-cash-generative peers.

Bears Say

Revenue Collapsed To ZeroReporting zero annual revenue in FY2025 signals a severe loss of core commercial activity. Over months this undermines margin sustainability, destroys recurring revenue streams, and requires rebuilding client relationships or new product traction for durable recovery, making near-term operational stability fragile.

Operating Losses Despite Net IncomeCore operations remain loss-making while net income is boosted by non-operating items, indicating earnings are not sustainable. Over the medium term this masks true profitability, hampers cash conversion expectations, and leaves the company dependent on one-offs or accounting items rather than improving core margins.

Volatile, Deteriorating Cash FlowRecent return to negative operating cash flow and historical volatility reduce the firm's ability to self-fund operations, R&D, or sales investments. Persisting cash weakness over months forces external financing or asset actions, increasing execution risk for any strategic turnaround or growth initiatives.

TAKE Solutions Limited News

TAKE Solutions Appoints New Non-Executive Director

TAKE Solutions Limited ( ($IN:TAKE) ) has provided an update. TAKE Solutions Limited has announced the appointment of...

2M ago

TAKE

TAKE Solutions Announces Director Resignation

The latest announcement is out from TAKE Solutions Limited ( ($IN:TAKE) ). TAKE Solutions Limited has announced the...

3M ago

TAKE

TAKE FAQ

What was TAKE Solutions Limited’s price range in the past 12 months?

TAKE Solutions Limited lowest stock price was ₹6.70 and its highest was ₹49.90 in the past 12 months.

What is TAKE Solutions Limited’s market cap?

TAKE Solutions Limited’s market cap is ₹6.99B.

When is TAKE Solutions Limited’s upcoming earnings report date?

TAKE Solutions Limited’s upcoming earnings report date is May 28, 2026 which is in 94 days.

How were TAKE Solutions Limited’s earnings last quarter?

TAKE Solutions Limited released its earnings results on Feb 14, 2026. The company reported ₹0.076 earnings per share for the quarter, beating the consensus estimate of N/A by ₹0.076.

Is TAKE Solutions Limited overvalued?

According to Wall Street analysts TAKE Solutions Limited’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does TAKE Solutions Limited pay dividends?

TAKE Solutions Limited pays a Semiannually dividend of ₹0.4 which represents an annual dividend yield of N/A. See more information on TAKE Solutions Limited dividends here

What is TAKE Solutions Limited’s EPS estimate?

TAKE Solutions Limited’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does TAKE Solutions Limited have?

TAKE Solutions Limited has 147,934,000 shares outstanding.

What happened to TAKE Solutions Limited’s price movement after its last earnings report?

TAKE Solutions Limited reported an EPS of ₹0.076 in its last earnings report, beating expectations of N/A. Following the earnings report the stock price went down -4.976%.

Which hedge fund is a major shareholder of TAKE Solutions Limited?

Currently, no hedge funds are holding shares in IN:TAKE

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Company Description

TAKE Solutions Limited

TAKE Solutions Limited, together with its subsidiaries, provides domain-intensive services and solutions in life sciences and supply chain management in the United States, the Asia Pacific, and Europe. The company offers IP-driven and technology backed solutions, consulting, and functional services across clinical, regulatory, and safety for life sciences industry. It also provides clinical research, generics development, data sciences, regulatory affairs, and pharmacovigilance/safety services. In addition, the company provides IT infrastructure and support, supply chain management, engineering, designing, and sourcing services. It serves to large and small innovator biopharmaceutical and devices companies, as well as generics manufacturers. The company was incorporated in 2000 and is headquartered in Chennai, India. TAKE Solutions Limited is a subsidiary of TAKE Solutions Pte. Limited.